nach oben

European Journal of Nutrition

Erschienen in:

08.05.2023 | Original Contribution

Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain–peripheral axis of GLP-1 through inhibition of DPP-4 function in mice

verfasst von: Chaitra Rai, Poornima Priyadarshini

Erschienen in: European Journal of Nutrition | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obesity is a growing global health concern. Recent literature indicates a prominent role of glucagon-like peptide-1 (GLP-1) in glucose metabolism and food intake. The synergistic action of GLP-1 in the gut and brain is responsible for its satiety-inducing effect, suggesting that upregulation of active GLP-1 levels could be an alternative strategy to combat obesity. Dipeptidyl peptidase-4 (DPP-4) is an exopeptidase known to inactivate GLP-1, suggesting that its inhibition could be a crucial strategy for effectively extending the half-life of endogenous GLP-1. Peptides derived from partial hydrolysis of dietary proteins are gaining traction due to their inhibitory activity on DPP-4.

Methods

Whey protein hydrolysate from bovine milk (bmWPH) was produced using simulated in situ digestion, purified using RP-HPLC, and characterized for DPP-4 inhibition. The antiadipogenic and antiobesity activity of bmWPH was then studied in 3T3-L1 preadipocytes and high-fat diet-induced obesity (HFD) mice model, respectively.

Results

The dose-dependent inhibitory effect of bmWPH on the catalytic activity of DPP-4 was observed. Additionally, bmWPH suppressed adipogenic transcription factors and DPP-4 protein levels, leading to a negative effect on preadipocyte differentiation. In an HFD mice model, co-administration of WPH for 20 weeks downregulated adipogenic transcription factors, resulting in a concomitant reduction in whole body weight and adipose tissues. Mice fed with bmWPH also showed a marked reduction in DPP-4 levels in WAT, liver, and serum. Furthermore, HFD mice fed with bmWPH exhibited increased serum and brain GLP levels, which led to a significant decrease in food intake.

Conclusion

In conclusion, bmWPH reduces body weight in HFD mice by suppressing appetite through GLP-1, a satiety-inducing hormone, in both the brain and peripheral circulation. This effect is achieved through modulation of both the catalytic and non-catalytic activity of DPP-4.

Nur mit Berechtigung zugänglich

Miralpeix C, Reguera AC, Fosch A et al (2021) Hypothalamic endocannabinoids in obesity: an old story with new challenges. Cell Mol Life Sci 78(23):7469–7490. https://doi.org/10.1007/s00018-021-04002-6CrossRefPubMedPubMedCentral

van Bloemendaal L, ten Kulve JS, La Fleur SE et al (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221(1):T1-16. https://doi.org/10.1530/JOE-13-0414CrossRefPubMed

Schroeder LE, Leinninger GM (2018) Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders. Biochim Biophys Acta—Mol Basis Dis 1864(3):900–916. https://doi.org/10.1016/j.bbadis.2017.12.036

Bauer PV, Hamr SC, Duca FA (2016) Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. Cell Mol Life Sci 73(4):737–755. https://doi.org/10.1007/s00018-015-2083-zCrossRefPubMed

Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418:650–654. https://doi.org/10.1038/NATURE00887CrossRefPubMed

Holst JJ (1994) Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107(6):1848–1855. https://doi.org/10.1016/0016-5085(94)90831-1CrossRefPubMed

Drucker DJ (1998) Perspectives in diabetes: glucagon-like peptides. Diabetes 47(2):159–169. https://doi.org/10.2337/diab.47.2.159CrossRefPubMed

Farooqui AA, Farooqui T, Panza F, Frisardi V (2012) Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 69(5):741–762. https://doi.org/10.1007/s00018-011-0840-1CrossRefPubMed

Tsang AH, Nuzzaci D, Darwish T et al (2020) Nutrient sensing in the nucleus of the solitary tract mediates non-aversive suppression of feeding via inhibition of AgRP neurons. Mol Metab 42:101070. https://doi.org/10.1016/j.molmet.2020.101070CrossRefPubMedPubMedCentral

10.

Brierley DI, Holt MK, Singh A et al (2021) Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 3:258–273. https://doi.org/10.1038/s42255-021-00344-4CrossRefPubMedPubMedCentral

11.

Dakin CL, Gunn I, Small CJ et al (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244–4250. https://doi.org/10.1210/ENDO.142.10.8430CrossRefPubMed

12.

Panjwani N, Mulvihill EE, Longuet C et al (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE −/− mice. Endocrinology 154(1):127–139. https://doi.org/10.1210/en.2012-1937CrossRefPubMed

13.

Le Roux CW, Aylwin SJB, Batterham RL et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114. https://doi.org/10.1097/01.SLA.0000183349.16877.84CrossRefPubMedPubMedCentral

14.

Lamers D, Famulla S, Wronkowitz N et al (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:1917–1925. https://doi.org/10.2337/DB10-1707CrossRefPubMedPubMedCentral

15.

Wronkowitz N, Görgens SW, Romacho T et al (1842) (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta - Mol Basis Dis 9:1613–1621. https://doi.org/10.1016/j.bbadis.2014.06.004CrossRef

16.

Chou E, Suzuma I, Way KJ et al (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105:373–379. https://doi.org/10.1161/HC0302.102143CrossRefPubMed

17.

Yoon YS, Uchida S, Masuo O et al (2005) Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111:2073–2085. https://doi.org/10.1161/01.CIR.0000162472.52990.36CrossRefPubMed

18.

Zhong J, Maiseyeu A, Davis SN, Rajagopalan S (2015) DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 116(8):1491–1504. https://doi.org/10.1161/CIRCRESAHA.116.305665CrossRefPubMedPubMedCentral

19.

Knudsen LB (2019) Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity. ACS Pharmacol Transl Sci 2:468–484. https://doi.org/10.1021/ACSPTSCI.9B00048CrossRefPubMedPubMedCentral

20.

Gregoire FM, Smas CM, Sul HS (1998) Understanding adipocyte differentiation. Physiol Rev 78(3):783–809. https://doi.org/10.1152/physrev.1998.78.3.783CrossRefPubMed

21.

Jakab J, Miškić B, Mikšić Š, et al (2021) Adipogenesis as a potential anti-obesity target: A review of pharmacological treatment and natural products. Diabetes Metab Syndr Obes Targets Ther 14:67–83. https://doi.org/10.2147/DMSO.S281186. (eCollection 2021)

22.

Mauro M, Taylor V, Wharton S, Sharma AM (2008) Barriers to obesity treatment. Eur J Intern Med 19:173–180. https://doi.org/10.1016/J.EJIM.2007.09.011CrossRefPubMed

23.

Konstantinidi M, Koutelidakis AE (2019) Functional foods and bioactive compounds: a review of its possible role on weight management and obesity’s metabolic consequences. Medicines 6(3):94. https://doi.org/10.3390/medicines6030094CrossRefPubMedPubMedCentral

24.

Chuang CC, Martinez K, Xie G et al (2010) Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 92(6):1511–1521. https://doi.org/10.3945/ajcn.2010.29807CrossRefPubMed

25.

van Heerden FR (2008) Hoodia gordonii: a natural appetite suppressant. J Ethnopharmacol 119(3):434–437. https://doi.org/10.1016/j.jep.2008.08.023CrossRefPubMed

26.

Hall WL, Millward DJ, Long SJ, Morgan LM (2003) Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br J Nutr 89:239–248. https://doi.org/10.1079/BJN2002760CrossRefPubMed

27.

Westerterp-Plantenga MS, Nieuwenhuizen A, Tomé D et al (2009) Dietary protein, weight loss, and weight maintenance. Annu Rev Nutr 29:21–41. https://doi.org/10.1146/ANNUREV-NUTR-080508-141056CrossRefPubMed

28.

Ewert J, Luz A, Volk V et al (2019) Enzymatic production of emulsifying whey protein hydrolysates without the need of heat inactivation. J Sci Food Agric 99:3443–3450. https://doi.org/10.1002/JSFA.9562CrossRefPubMed

29.

Krissansen GW (2007) Emerging health properties of whey proteins and their clinical implications. J Am Coll Nutr 26(6):713S-S723. https://doi.org/10.1080/07315724.2007.10719652CrossRefPubMed

30.

Jeewanthi RKC, Kim MH, Lee NK et al (2017) peptide analysis and the bioactivity of whey protein hydrolysates from cheese whey with several enzymes. Korean J food Sci Anim Resour 37:62–70. https://doi.org/10.5851/KOSFA.2017.37.1.62CrossRefPubMedPubMedCentral

31.

Nongonierma AB, Lalmahomed M, Paolella S, FitzGerald RJ (2017) Milk protein isolate (MPI) as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. Food Chem 231:202–211. https://doi.org/10.1016/J.FOODCHEM.2017.03.123CrossRefPubMed

32.

Bendtsen LQ, Lorenzen JK, Bendsen NT et al (2013) Effect of dairy proteins on appetite, energy expenditure, body weight, and composition: a review of the evidence from controlled clinical trials. Adv Nutr 4(4):418–438. https://doi.org/10.3945/an.113.003723CrossRefPubMedPubMedCentral

33.

Walsh DJ, Bernard H, Murray BA et al (2004) In vitro generation and stability of the lactokinin β-lactoglobulin fragment (142–148). J Dairy Sci 87: (11):3845–57. https://doi.org/10.3168/jds.S0022-0302(04)73524-CrossRefPubMed

34.

Majid A, Lakshmikanth M, Lokanath NK, Poornima Priyadarshini CG (2022) Generation, characterization and molecular binding mechanism of novel dipeptidyl peptidase-4 inhibitory peptides from sorghum bicolor seed protein. Food Chem 369:130888. https://doi.org/10.1016/j.foodchem.2021.130888CrossRefPubMed

35.

Kumar R, Joshi R, Kumari M et al (2020) Elevated CO2 and temperature influence key proteins and metabolites associated with photosynthesis, antioxidant and carbon metabolism in Picrorhiza kurroa. J Proteomics 219:103755. https://doi.org/10.1016/j.jprot.2020.103755CrossRefPubMed

36.

Rai C, Nandini CD, Priyadarshini P (2021) Composition and structure elucidation of bovine milk glycosaminoglycans and their anti-adipogenic activity via modulation PPAR-γ and C/EBP-α. Int J Biol Macromol 193(Pt A):137–144. https://doi.org/10.1016/j.ijbiomac.2021.10.076CrossRefPubMed

37.

Wang CY, Liao JK (2012) A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol 821:421–433. https://doi.org/10.1007/978-1-61779-430-8_27CrossRefPubMedPubMedCentral

38.

Fischer AH, Jacobson K, Rose J, Zeller R (2005) Hematoxylin and Eosin ( H & E ) staining. CSH Protoc. https://doi.org/10.1101/pdb.prot4986CrossRef

39.

Bird B, Rowlette J (2017) A protocol for rapid, label-free histochemical imaging of fibrotic liver. Analyst 142(8):1179–1184. https://doi.org/10.1039/c6an02080aCrossRefPubMed

40.

Zilleßen P, Celner J, Kretschmann A et al (2016) Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes. Sci Rep 6:23074. https://doi.org/10.1038/srep23074CrossRefPubMedPubMedCentral

41.

Frid AH, Nilsson M, Holst JJ, Björck IME (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82(1):69–75. https://doi.org/10.1093/ajcn/82.1.69CrossRefPubMed

42.

Minj S, Anand S (2020) Whey proteins and its derivatives: Bioactivity, functionality, and current applications. Dairy 1(3):233–258. https://pubmed.ncbi.nlm.nih.gov/?term=Minj%2C+S.%2C+%26+Anand%2C+S.+%282020%29.+Whey+proteins+and+its+derivatives%3A+Bioactivity%2C+functionality%2C+and+current+applications.+Dairy%2C+1%283%29%2C+233-258. Accessed 9 Mar 2022

43.

Nongonierma AB, Cadamuro C, Le Gouic A et al (2019) Dipeptidyl peptidase IV (DPP-IV) inhibitory properties of a camel whey protein enriched hydrolysate preparation. Food Chem 279:70–79. https://doi.org/10.1016/j.foodchem.2018.11.142CrossRefPubMed

44.

Nongonierma AB, Mazzocchi C, Paolella S, FitzGerald RJ (2017) Release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from milk protein isolate (MPI) during enzymatic hydrolysis. Food Res Int 94:79–89. https://doi.org/10.1016/j.foodres.2017.02.004CrossRefPubMed

45.

Song JJ, Wang Q, Du M et al (2017) Identification of dipeptidyl peptidase-IV inhibitory peptides from mare whey protein hydrolysates. J Dairy Sci 100(9):6885–6894. https://doi.org/10.3168/jds.2016-11828CrossRefPubMed

46.

Çakır B, Okuyan B, Şener G, Tunali-Akbay T (2021) Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): in silico analysis. Eur J Pharmacol 891:173781. https://doi.org/10.1016/j.ejphar.2020.173781CrossRefPubMed

47.

Martínez-Sánchez SM, Gabaldón-Hernández JA, Montoro-García S (2020) Unravelling the molecular mechanisms associated with the role of food-derived bioactive peptides in promoting cardiovascular health. J Funct Foods. https://doi.org/10.1016/j.jff.2019.103645CrossRef

48.

Roberts PR, Burney JD, Black KW, Zaloga GP (1999) Effect of chain length on absorption of biologically active peptides from the gastrointestinal tract. Digestion 60(4):332–337. https://doi.org/10.1159/000007679CrossRefPubMed

49.

Das SS, Hayashi H, Sato T et al (2014) Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose. Diabetes, Metab Syndr Obes Targets Ther 7:185–194. https://doi.org/10.2147/DMSO.S62610CrossRef

50.

Jiang S, Wu X, Wang Y et al (2020) The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway. Eur J Pharmacol 882. https://doi.org/10.1016/j.ejphar.2020.173272CrossRefPubMed

51.

Jiang S, Wu X, Wang Y et al (2020) The potential DPP-4 inhibitors from Xiao-Ke-An improve the glucolipid metabolism via the activation of AKT/GSK-3β pathway. Eur J Pharmacol 882:173272. https://doi.org/10.1016/j.ejphar.2020.173272CrossRefPubMed

52.

D’souza K, Mercer A, Mawhinney H et al (2020) Whey peptides stimulate differentiation and lipid metabolism in adipocytes and ameliorate lipotoxicity-induced insulin resistance in muscle cells. Nutrients 12(2):425. https://doi.org/10.3390/nu12020425CrossRefPubMedPubMedCentral

53.

de Castro RJS, Inacio RF, de Oliveira ALR, Sato HH (2016) Statistical optimization of protein hydrolysis using mixture design: development of efficient systems for suppression of lipid accumulation in 3T3-L1 adipocytes. Biocatal Agric Biotechnol 5:17–23. https://doi.org/10.1016/j.bcab.2015.12.004CrossRef

54.

Karami Z, Akbari-adergani B (2019) Bioactive food derived peptides: a review on correlation between structure of bioactive peptides and their functional properties. J Food Sci Technol 56(2):535–547CrossRefPubMedPubMedCentral

55.

Takeda K, Sawazaki H, Takahashi H et al (2018) The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice. FEBS Open Bio 8(11):1782–1793. https://doi.org/10.1002/2211-5463.12498CrossRefPubMedPubMedCentral

56.

Beiroa D, Imbernon M, Gallego R et al (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63(10):3346–3358. https://doi.org/10.2337/db14-0302CrossRefPubMed

57.

Klemann C, Wagner L, Stephan M, von Hörsten S (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol 185(1):1–21. https://doi.org/10.1111/cei.12781CrossRefPubMedPubMedCentral

58.

Liu F, Zhu X, Jiang X et al (2022) Transcriptional control by HNF-1: Emerging evidence showing its role in lipid metabolism and lipid metabolism disorders. Genes Dis 9(5):1248–1257. https://doi.org/10.1016/j.gendis.2021.06.010.eCollectionCrossRefPubMed

59.

͆lusarz A, Pulakat L, (2015) The two faces of miR-29. J Cardiovasc Med 16(7):480–490. https://doi.org/10.2459/JCM.0000000000000246CrossRef

60.

Turcot V, Bouchard L, Faucher G et al (2011) DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity 19(2):388–395. https://doi.org/10.1038/oby.2010.198CrossRefPubMed

61.

Xu SP, Mao XY, Ren FZ, Che HL (2011) Attenuating effect of casein glycomacropeptide on proliferation, differentiation, and lipid accumulation of in vitro Sprague-Dawley rat preadipocytes. J Dairy Sci 94(2):676–683. https://doi.org/10.3168/jds.2010-3827CrossRefPubMed

62.

Kim YM, Kim IH, Choi JW et al (2015) The anti-obesity effects of a tuna peptide on 3T3-L1 adipocytes are mediated by the inhibition of the expression of lipogenic and adipogenic genes and by the activation of the Wnt/β-catenin signaling pathway. Int J Mol Med 36(2):327–334. https://doi.org/10.3892/ijmm.2015.2231CrossRefPubMedPubMedCentral

63.

Zhang X, Shi W, He H et al (2020) Hypolipidemic effects and mechanisms of Val-Phe-Val-Arg-Asn in C57BL/6J mice and 3T3-L1 cell models. J Funct Foods 73:104100. https://doi.org/10.1016/j.jff.2020.104100CrossRef

64.

Chakrabarti S, Wu J (2015) Milk-derived tripeptides IPP (Ile-Pro-Pro) and VPP (Val-Pro- Pro) promote adipocyte differentiation and inhibit inflammation in 3T3-F442A cells. PLoS One 10(2):e0117492. https://doi.org/10.1371/journal.pone.0117492CrossRefPubMedPubMedCentral

65.

Pratley RE, Salsali A (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23(4):919–931. https://doi.org/10.1185/030079906x162746CrossRefPubMed

66.

Gutzwiller JP, Drewe J, Göke B et al (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol—Regul Integr Comp Physiol 276(5):R1541–R1544. https://doi.org/10.1152/ajpregu.1999.276.5.r1541CrossRef

67.

de Fonseca RR, Navarro M, Alvarez E et al (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49(6):709–717. https://doi.org/10.1053/meta.2000.6251CrossRef

68.

Abbott CR, Monteiro M, Small CJ et al (2005) The inhibitory effects of peripheral administration of peptide YY 3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044(1):127–131. https://doi.org/10.1016/j.brainres.2005.03.011CrossRefPubMed

69.

Marguet D, Baggio L, Kobayashi T et al (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97(12):6874–6879. https://doi.org/10.1073/pnas.120069197CrossRefPubMedPubMedCentral

70.

Katsuyama H, Adachi H, Hamasaki H, et al (2014) Significant differences in effects of sitagliptin treatment on body weight and lipid metabolism between obese and non-obese patients with type 2 diabetes. J Endocrinol Metab 4:136–142. https://doi.org/10.14740/jem243w

71.

Chae YN, Kim TH, Kim MK et al (2015) Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice. PLoS One 10(12):e0144064. https://doi.org/10.1371/journal.pone.0144064CrossRefPubMedPubMedCentral

72.

Deacon CF, Pridal L, Klarskov L et al (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol—Endocrinol Metab 271(3 Pt 1):E458–E464. https://doi.org/10.1152/ajpendo.1996.271.3.e458CrossRef

73.

Wang X, Ke J, Zhu Y, Jun et al (2021) Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discov 7(1):236. https://doi.org/10.1038/s41420-021-00625-7CrossRefPubMedPubMedCentral

74.

Berthoud HR, Albaugh VL, Neuhuber WL (2021) Gut-brain communication and obesity: Understanding functions of the vagus nerve. J Clin Invest 131(10):e143770. https://doi.org/10.1172/JCI143770CrossRefPubMedPubMedCentral

75.

Ørskov C, Poulsen SS, Møller M, Holst JJ (1996) Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45(6):832–835. https://doi.org/10.2337/diab.45.6.832CrossRefPubMed

76.

Korner J, Bessler M, Inabnet W et al (2007) Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3(6):597–601. https://doi.org/10.1016/j.soard.2007.08.004CrossRefPubMedPubMedCentral

77.

Whitcomb DC, Taylor IL (1992) A new twist in the brain-gut axis. Am J Med Sci 304(5):334–8. https://doi.org/10.1097/00000441-199211000-00001CrossRefPubMed

78.

Kastin AJ, Akerstrom V, Pan W (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18(1–2):7–14. https://doi.org/10.1385/JMN:18:1-2:07CrossRefPubMed

79.

Brierley DI, Holt MK, Singh A et al (2021) Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 3(2):258–273. https://doi.org/10.1038/s42255-021-00344-4CrossRefPubMedPubMedCentral

80.

Parker JA, McCullough KA, Field BCT et al (2013) Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes 37(10):1391–1398. https://doi.org/10.1038/ijo.2012.227CrossRef

81.

Dalvi PS, Nazarians-Armavil A, Purser MJ, Belsham DD (2012) Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology 153(5):2208–2222. https://doi.org/10.1210/en.2011-1795CrossRefPubMed

82.

Yaribeygi H, Atkin SL, Sahebkar A (2019) Natural compounds with DPP-4 inhibitory effects: implications for the treatment of diabetes. J Cell Biochem 120(7):10909–10913. https://doi.org/10.1002/jcb.28467CrossRefPubMed

83.

Doupis J, Veves A (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther 25(7):627–643. https://doi.org/10.1007/s12325-008-0076-1CrossRefPubMed

84.

Tulipano G, Sibilia V, Caroli AM, Cocchi D (2011) Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 32(4):835–838. https://doi.org/10.1016/j.peptides.2011.01.002CrossRefPubMed

85.

Gaudel C, Nongonierma AB, Maher S et al (2013) A whey protein hydrolysate promotes insulinotropic activity in a clonal pancreatic β-cell line and enhances glycemic function in ob/ob mice. J Nutr 143(7):1109–1114. https://doi.org/10.3945/jn.113.174912CrossRefPubMed

86.

Marques AP, Cunha-Santos J, Leal H et al (1862) (2018) Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice. Biochim Biophys Acta—Gen Subj 3:403–413. https://doi.org/10.1016/j.bbagen.2017.11.012CrossRef

87.

Da Silva MS, Bigo C, Barbier O, Rudkowska I (2017) Whey protein hydrolysate and branched-chain amino acids downregulate inflammation-related genes in vascular endothelial cells. Nutr Res 38:43–51. https://doi.org/10.1016/j.nutres.2017.01.005CrossRefPubMed

88.

Ma Y, Liu J, Shi H, Yu L, (Lucy) (2016) Isolation and characterization of anti-inflammatory peptides derived from whey protein. J Dairy Sci 99(9):6902–6912. https://doi.org/10.3168/jds.2016-11186CrossRefPubMed

89.

Zeng Y, Li C, Guan M et al (2014) The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol 13:32. https://doi.org/10.1186/1475-2840-13-32CrossRefPubMedPubMedCentral

90.

Dobrian AD, Ma Q, Lindsay JW et al (2011) Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol—Endocrinol Metab 300(2):E410–E421. https://doi.org/10.1152/ajpendo.00463.2010CrossRefPubMed

Titel: Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain–peripheral axis of GLP-1 through inhibition of DPP-4 function in mice
verfasst von: Chaitra Rai
Poornima Priyadarshini
Publikationsdatum: 08.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 6/2023
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-023-03162-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain–peripheral axis of GLP-1 through inhibition of DPP-4 function in mice

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

mTOR pathway candidate genes and energy intake interaction on breast cancer risk in Black women from the Women’s Circle of Health Study

Relationship between food-derived antioxidant vitamin intake and breast cancer risk: a mendelian randomized study

Associations of healthful and unhealthful plant-based diets with plasma markers of cardiometabolic risk

Nut and seed consumption is inversely associated with metabolic syndrome in females but not males: findings from the 2005–2018 NHANES data

Hippocampal neurogenesis and Arc expression are enhanced in high-fat fed prepubertal female pigs by a diet including omega-3 fatty acids and Bifidobacterium breve CECT8242

Maternal diet supplementation with high-docosahexaenoic-acid canola oil, along with arachidonic acid, promotes immune system development in allergy-prone BALB/c mouse offspring at 3 weeks of age

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin